2019 Novel Coronavirus (COVID-19)

South Dakota Department of Health

April 14, 2022

We will begin in just a few moments. Thanks!

Not intended for press or for reporting purposes.
This is an **emerging, rapidly evolving situation**. Information in this presentation is current as of April 13, 2022. Please check the South Dakota Department of Health website for the most current information and guidance.

[COVID.sd.gov](https://COVID.sd.gov)
Agenda

• Situation Update
• Laboratory Guidance
• Vaccination Update
• Infection Prevention
• Community Mitigation
• Supply Chain Management
• On-going Communications
• Q&A Session

Not intended for press or for reporting purposes.
Situation Update

Not intended for press or for reporting purposes.
Coronavirus Situation

- **International**
  - 497,960,492 confirmed cases
    - 6,181,850 deaths
- **United States** (50 states + DC)
  - 79,647,331 confirmed cases
    - 978,118 deaths
- **South Dakota**
  - 237,370 confirmed and probable cases
    - 2,898 deaths
    - 234,056 recovered cases

As of April 13th, 2022

Not intended for press or for reporting purposes.
Epidemiologic “Epi” Curve of COVID-19 Cases, by Date Reported to SD-DOH

Cases by Date Reported to SD-DOH

As of April 13th, 2022

Not intended for press or for reporting purposes.
COVID-19 Case Map, by County

As of April 13th, 2022

Not intended for press or for reporting purposes.

<table>
<thead>
<tr>
<th>Community Spread</th>
<th>Number of Counties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>34</td>
</tr>
<tr>
<td>Moderate</td>
<td>18</td>
</tr>
<tr>
<td>Substantial</td>
<td>2</td>
</tr>
<tr>
<td>High</td>
<td>12</td>
</tr>
</tbody>
</table>

COVID-19 Community Levels can be found at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html
General Testing Recommendations

Medical providers are recommended to test individuals (1) identified as a close contact to a person with COVID-19 or (2) signs and symptoms compatible with COVID-19 infection, including:

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea


Not intended for press or for reporting purposes.
Reporting COVID-19 Tests to SD-DOH

• **Reminder**: Coronavirus respiratory syndromes are a Category I disease

• Report *immediately* on suspicion of disease

• Reporting mechanisms:
  • Electronic Laboratory Report (ELR) – HL7 message to SD Health Link (health information exchange)
  • Flat file (CSV) – Secure email
  • Disease reporting website – [sd.gov/diseasereport](http://sd.gov/diseasereport)
    • **Ensure patient phone numbers are included**
  • Fax – 605.773.5509


_Not intended for press or for reporting purposes._
As of April 13th, 2022

Percent of Cases (distribution of cases across age groups)
Percent Hospitalized (of cases within age groups)
Percent Died (of cases within age groups)

Cumulative Period: March 2020 to March 2022
Delta Period: July 2021 to December 2021
Omicron Period: January 2022 to March 2022

Not intended for press or for reporting purposes.
### Breakthrough, Variant, and Reinfection Cases

As of April 13th, 2022

**Breakthrough Cases**

<table>
<thead>
<tr>
<th></th>
<th>#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>38,499</td>
</tr>
<tr>
<td>Hospitalized</td>
<td>1,367</td>
</tr>
<tr>
<td>Died</td>
<td>290</td>
</tr>
</tbody>
</table>

**Variant Cases**

<table>
<thead>
<tr>
<th></th>
<th>#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>1,914</td>
</tr>
<tr>
<td>Hospitalized</td>
<td>92</td>
</tr>
<tr>
<td>Died</td>
<td>21</td>
</tr>
</tbody>
</table>

**Reinfection**

<table>
<thead>
<tr>
<th></th>
<th>#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>10,253</td>
</tr>
<tr>
<td>Hospitalized</td>
<td>220</td>
</tr>
<tr>
<td>Died</td>
<td>36</td>
</tr>
</tbody>
</table>

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 COVID-NET, 14 States, March 2020–February 2022

COVID-19 hospitalization rates among children ages 4 and younger were 5x as high during the peak of Omicron compared with Delta.

Get vaccinated to help protect yourself and those too young to be vaccinated.

*Week ending September 11, 2021 (Delta peak) compared with week ending January 8, 2022 (Omicron peak)

https://www.cdc.gov/mmwr/volumes/71/wr/mm7111e2.htm?s_cid=mm7111e2_w

Not intended for press or for reporting purposes.
Use of At-Home COVID-19 Tests
United States, August 23, 2021–March 12, 2022

Knowing if you have COVID-19 can help you get early treatment and protect others
AT-HOME TESTS ARE WIDELY AVAILABLE AND EASY TO USE

At-home test use has increased over time*

Self-reported At-home Test Use %

Among those with COVID-like illness
Among all respondents

Omicron

Get tested if:

- Symptomatic — test immediately
- Exposed — test at least 5 days after exposure
- Going to an indoor gathering, especially if around people at increased risk

*Mathematical, nonprobability-based online survey of 418,279 U.S. adults, August 23, 2021–March 12, 2022

Not intended for press or for reporting purposes.

https://www.cdc.gov/mmwr/volumes/71/ww/mm7113e1.htm?s_cid=mm7113e1_w

COVIDtests.gov
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination
PCORnet, United States, January 2021–January 2022

Risk of heart complications* is higher after COVID-19 infection than after mRNA COVID-19 vaccination among males and females of all ages

TEEN BOYS (ages 12–17 years) had
2–6x
the risk of heart complications after infection compared to after vaccination†

YOUNG MEN (ages 18–29 years) had
7–8x
the risk of heart complications after infection compared to after vaccination†

COVID-19 vaccination is the best way to protect against COVID-19 and rare heart complications

*Myocarditis, pericarditis, or multisystem inflammatory syndrome among U.S. patients in 40 healthcare systems, Jan 1, 2021–Jan 31, 2022
†Compared with the risk after second dose of mRNA COVID-19 vaccine

https://www.cdc.gov/mmwr/volumes/71/wr/mm7114e1.htm?s_cid=mm7114e1_w

Not intended for press or for reporting purposes.
Selected CDC Updates

Available at: https://www.cdc.gov/coronavirus/2019-ncov/whats-new-all.html

COVID Data Tracker: https://covid.cdc.gov/covid-data-tracker/#datatracker-home


Not intended for press or for reporting purposes.
Laboratory Guidance
Supply Chain Updates:

- Supply chains continue to strengthen.
- Manufacturers meeting demand while focusing on large contract orders.
- Major vendors stocking NAAT and non-NAAT tests and supplies.
- No update from the federal government regarding future purchases and distribution of test kits and materials.
COVID Testing Resources

- For questions about DOH testing support, please contact:
  - FQHC, CHC, Rural Clinics: Kaitlin.Thomas@state.sd.us
  - Long-term Care: Denise.Broadbent@state.sd.us
  - Healthcare: Laurie.Gregg@state.sd.us
  - EMS: Marty.Link@state.sd.us
  - Pharmacies: Bob.Coolidge@state.sd.us
  - K-12 Schools: Joe.Moran@state.sd.us
  - Higher Education: Laurie.Gregg@state.sd.us
  - Childcare Providers: Laura.Nordbye@state.sd.us
  - Businesses: John.Osburn@state.sd.us
  - Confinement Facilities: Staci@southdakotasheriffs.org

- Inquiries for Abbott BinaxNOW and ID NOW should be sent to: Dorothy.Ahten@abbott.com

- Inquiries for COVID-19 testing resources can also be sent to: Matt.VanDam@McKesson.com

- Free COVID-19 tests kits are also available from the federal government at: https://www.covidtests.gov/
COVID-19 Pandemic Response, Laboratory Data Reporting: CARES Act Section 18115

- On March 8, CDC released new guidance for federal HHS laboratory reporting requirements that will take effect on April 4, 2022.
- New reporting requirements are summarized below.

<table>
<thead>
<tr>
<th>Setting</th>
<th>Test Type</th>
<th>Positive Results</th>
<th>Negative Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLIA Moderate/High</td>
<td>NAAT</td>
<td>Report</td>
<td>Report</td>
</tr>
<tr>
<td>CLIA Moderate/High</td>
<td>Non-NAAT</td>
<td>Report</td>
<td>Optional</td>
</tr>
<tr>
<td>CLIA Waived(^1)</td>
<td>Non-NAAT</td>
<td>Report</td>
<td>Optional</td>
</tr>
<tr>
<td>At-Home/OTC</td>
<td>Non-NAAT</td>
<td>Optional</td>
<td>Optional</td>
</tr>
<tr>
<td>Any Setting</td>
<td>Antibody</td>
<td>Optional</td>
<td>Optional</td>
</tr>
</tbody>
</table>

\(^1\)Examples of CLIA Waived settings might include K-12 schools, correctional facilities, childcare facilities, drive-through testing sites, medical provider offices, pharmacies, etc.
Planning and Milestones for 2022-2023

SARS-CoV-2 Testing Support
• Ensure availability of antigen test kits for academic institution through the 2021-2022 academic year
• Continued support childcare and other summer programs
• Continued support for major events such as Sturgis Rally and State Fair
• Stage antigen test kits at academic institution prior to the start of the 2022-2023 academic year
• Ensure readiness for potential surges in testing especially during the 2022-2023 respiratory season
• Continued support for LTC, IHS and Tribes, and Healthcare partners throughout the year
COVID Therapy Updates
## FDA EUA-Approved COVID-19 Therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Category</th>
<th>Manufacturer</th>
<th>Availability</th>
<th>Demand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bamcanivimab</td>
<td>Monoclonal Antibody</td>
<td>Eli Lilly</td>
<td>Restricted</td>
<td>NA</td>
</tr>
<tr>
<td>Etesevimab</td>
<td>Monoclonal Antibody</td>
<td>Eli Lilly</td>
<td>Restricted</td>
<td>NA</td>
</tr>
<tr>
<td>REGEN-COV</td>
<td>Monoclonal Antibody</td>
<td>Regeneron</td>
<td>Restricted</td>
<td>NA</td>
</tr>
<tr>
<td>Sotrovimab</td>
<td>Monoclonal Antibody</td>
<td>GlaxoSmithKline</td>
<td>Restricted</td>
<td>NA</td>
</tr>
<tr>
<td>Bebtelovimab</td>
<td>Monoclonal Antibody</td>
<td>Eli Lilly</td>
<td>Federal Allocation</td>
<td>Low</td>
</tr>
<tr>
<td>Evusheld</td>
<td>Monoclonal Antibody (PrEP)</td>
<td>AstraZeneca</td>
<td>Federal Allocation</td>
<td>Low</td>
</tr>
<tr>
<td>Molnupiravir</td>
<td>Oral Antiviral</td>
<td>Merck/Ridgeback</td>
<td>Federal Allocation</td>
<td>Low</td>
</tr>
<tr>
<td>Paxlovid</td>
<td>Oral Antiviral</td>
<td>Pfizer</td>
<td>Federal Allocation</td>
<td>Low</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>Intravenous Antiviral</td>
<td>Gilead</td>
<td>Open Market</td>
<td>No Data</td>
</tr>
</tbody>
</table>
Test to Treat

• A nationwide “Test to Treat” initiative was launched by the federal government to increase access to oral antiviral therapies for individuals with COVID-19.

• Test to Treat established locations in pharmacy-based clinics, federally-qualified community health centers (FQHCs), and long-term care facilities.

• SD has a network of pharmacies capable of moving COVID therapeutics throughout the state.

• 22 healthcare partner pharmacies in South Dakota are eligible to receive federal allocation of COVID therapeutics.

• Over 40 pharmacies enrolled in federal programs that support long-term care facilities in South Dakota.
Vaccination Update
COVID Vaccine coverage by age as of 04/12/2022

Not intended for press or for reporting purposes.
Following **FDA’s regulatory action on** March 29, 2022, the Centers for Disease Control and Prevention (CDC) has updated its **COVID-19 vaccination guidance** to give some individuals the option to receive a second booster dose using an mRNA COVID-19 vaccine. These individuals include:

- People ages 50 years and older who received an initial COVID-19 booster dose (regardless of which vaccine was used) at least 4 months ago;
- People ages 12 years and older who are moderately or severely immunocompromised who received an initial COVID-19 booster dose (regardless of which vaccine was used) at least 4 months ago; and
- People ages 18 years and older who received both a primary dose and a booster dose of J&J/Janssen COVID-19 vaccine at least 4 months ago.

Not intended for press or for reporting purposes.
Weekly doses administered reported to SDIIS

Not intended for press or for reporting purposes.
Public Dashboard – Weekly Updates 04-06-22

Total Doses Administered*

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th># of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen</td>
<td>37,748</td>
</tr>
<tr>
<td>Moderna</td>
<td>472,346</td>
</tr>
<tr>
<td>Pfizer</td>
<td>677,308</td>
</tr>
</tbody>
</table>

Total Persons Administered a Vaccine*

<table>
<thead>
<tr>
<th>Doses</th>
<th># of Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen - Series complete</td>
<td>35,042</td>
</tr>
<tr>
<td>Janssen - Booster dose</td>
<td>2,705</td>
</tr>
<tr>
<td>Moderna - 1 dose</td>
<td>25,622</td>
</tr>
<tr>
<td>Moderna - Series complete</td>
<td>175,029</td>
</tr>
<tr>
<td>Moderna - 3rd/Booster dose</td>
<td>91,464</td>
</tr>
<tr>
<td>Pfizer - 1 dose</td>
<td>34,391</td>
</tr>
<tr>
<td>Pfizer - Series complete</td>
<td>259,353</td>
</tr>
<tr>
<td>Pfizer - 3rd/Booster dose</td>
<td>118,955</td>
</tr>
</tbody>
</table>

Percent of State Population with at least 1 Dose**

- 1 dose: 71.91%
- Series Complete: 58.87%
- Booster dose: 33.13%

Based on 2019 Census Estimate for aged 5+ years (1 dose and Series Complete) and 16+ years (Booster dose).

Not intended for press or for reporting purposes.
HRSA Uninsured Administration
Reimbursement

Ceased on April 5 at 11:59 PM

Further, FAQs about the claims submission deadlines are online at:
https://www.hrsa.gov/coviduninsuredclaim
https://www.hrsa.gov/covid19-coverage-assistance

Not intended for press or for reporting purposes.
Infection Prevention Updates and Resources for Healthcare Facilities

Not intended for press or for reporting purposes.
• **CDC COVID-19 Guidance**: Below is a list of healthcare IPC and other related guidance documents that have been recently published or updated by CDC. For additional updates, CDC’s [What’s New & Updated](#) tool is a helpful way to stay up-to-date with new and updated content on CDC’s COVID-19 webpages. Users can filter by date, webpage type, audience, and topic.
  - [COVID-19 Vaccine Booster Shots](#) (3/30/22)
  - [Clinical Questions about COVID-19: Questions and Answers](#) (3/24/22)

• **CMS Updates**: Please see below for recent updates from CMS that may be relevant to HAI/AR programs.
  - [Clinical Laboratory Improvement Amendments of 1988 (CLIA) CMS Location and State Agency Updates to COVID-19 Survey Prioritization Guidance- QSO-22-14-CLIA](#) (3/22/22)
  - [Nursing Home Visitation - COVID-19 QSO-20-39-NH (REVISED)](#) (3/10/22)
  - [Interim Final Rule (IFC), CMS-3401-IFC, Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency related to Long-Term Care (LTC) Facility Testing Requirements – QSO-20-38-NH (REVISED)](#) (3/10/22)

_Not intended for press or for reporting purposes._
Note: CDC has updated guidance about COVID-19 community levels along with recommended individual and household-precautions and community-level prevention strategies that should be taken at each level. The rationale for these changes are described in the guidance. These COVID-19 community level recommendations do not apply in healthcare settings, such as hospitals and nursing homes. Healthcare settings should continue to follow CDC’s infection prevention and control recommendations for healthcare settings, which continue to use community transmission levels as a metric for stratifying some IPC measures (e.g., use of source control, screening testing).
Infection Prevention & Control Assessment Tool (ICARs) for LTC and ALF

How does a COVID ICAR benefit my ALF or LTC facility?

*Non-regulatory & FREE: Talk one-on-one with an infection preventionist and an infectious disease doctor to see how your facility is REALLY doing during the pandemic.

*Not just a checklist: While the CDC ICAR guides the discussion, the team talks through scenarios that are relevant to YOUR facility. They can compare what worked last year vs. what works now and review the latest guidelines, science and updates.

*Above and Beyond: Sharing tips and tricks on what works for other facilities in South Dakota and what might also work for you. Topics like vaccination uptake in staff, addressing PPE Fatigue, and reinforcing what you are doing RIGHT.

*Feedback after the ICAR to have on file for your facility. Something you can refer to when needed in the future!

Not intended for press or for reporting purposes.
WE ARE PROJECT FIRSTLINE

SD PROJECT FIRSTLINE.
IT’S NOT JUST TRAINING. IT’S TRAINING THAT CAN SAVE LIVES.

CONTACT US

SIMPLE THINGS WE CAN ALL DO to break the chain of infection -- wash hands often, cover your cough, stay home if sick, clean frequently touched surfaces at home/office (cell phones, laptops, car). Doing these things helps to prevent ANY infectious disease, from COVID-19 to the flu to a cold.

CHERI FAST
Project Firstline Program Manager
Cheri.fast@sdfmc.org

CHARLOTTE HOBER
Project Firstline Communications Director
Charlotte.hofer@sdfmc.org

SOUTH DAKOTA PROJECT FIRSTLINE
www.SDProjectFirstline.org
@ProjectFirstlineSouthDakota

Not intended for press or for reporting purposes.
Infection Control Questions? Contact Us:

Kipp Stahl kipp.stahl@state.sd.us
Community Mitigation
Not intended for press or for reporting purposes.
Supply Chain Management
All requests for PPE from DOH must be:

• Emailed to COVIDResourceRequests@state.sd.us,
• Fax to 605.773.5942, or
• Called in to 605.773.3048 to ensure prioritization and coordination of requests.

• Do not duplicate your request by using all three means of communication.

• Any requests received through any other email or number will all be directed to email COVIDResourceRequests@state.sd.us OR call 605.773.3048 and requesting entities must provide information regarding their current facility status.
On-going Communication

Not intended for press or for reporting purposes.
Helpful sources of information:

covid.sd.gov

coronavirus.gov

• SD COVID-19 Help Line: 800-997-2880
Communications

- SD-HAN: sdhan.sd.gov
- Epi Listserv
- Lab Listserv
- HAI Listserv
- OLC Listserv

Visit covid.sd.gov to subscribe

SOUTH DAKOTA COVID-19 INFORMATION LINE
Questions about COVID-19? We’re here to help.

Please call 1-800-997-2880

Not intended for press or for reporting purposes.
Questions?

Follow-up after the webinar
COVID Helpline: 800-997-2880
Epidemiology: 605-773-3737
Laboratory: 605-773-3368

COVID.sd.gov

Not intended for press or for reporting purposes.